(Total Views: 357)
Posted On: 09/30/2022 12:27:05 PM
Post# of 1418
Quote:
“The allowance of these two seminal pieces of intellectual property underlying the Company’s TBIA FTIR pan-cancer diagnosis platform, which we believe will ultimately outcompete the liquid biopsy platform for routine testing of asymptomatic and early-stage cancer patients , including tests such as Illumina’s Galleri ® ,” said Gerald Commissiong, President & CEO of Todos Medical.
These tests are money makers (and life savers). Illumina’s Galleri cost $950. Some cancer test can run up to $5000. Illumina stock (NASDAQ: ILMN) has a $30B market cap. Illumina reacquired GRAIL last year after spinning them off 4 years prior. GRAIL had the Galleri test.
GRAIL was reacquired for $3.5B. This puts 3CL Pharma into perspective. Todos could buy the rest of the company this year or do it later at possibly a much higher price.
https://investor.illumina.com/news/press-rele...fault.aspx
(1)
(0)
